Entries |
Document | Title | Date |
20110009320 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 01-13-2011 |
20110039776 | FUSION PEPTIDE THERAPEUTIC COMPOSITIONS - Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life, etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs. | 02-17-2011 |
20110092424 | PRODUCTION OF GLUCAGON LIKE PEPTIDE 2 AND ANALOGS - GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In a specific embodiment, [Gly | 04-21-2011 |
20110098222 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues. | 04-28-2011 |
20110172152 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 07-14-2011 |
20110178014 | PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 07-21-2011 |
20110190205 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide - The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide. | 08-04-2011 |
20110230409 | GLP-I Agonist And Cardiovascular Complications - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 09-22-2011 |
20110237510 | STABILIZED GLUCAGON SOLUTIONS - A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C. | 09-29-2011 |
20110245173 | Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction - The present invention generally provides polypeptide analogues of GLP-‘(9-34) and GLP-1 (9-36) that have increased in vivo half-lives resulting from reduced susceptibility to proteolytic enzymes. Other aspects of the invention relate to methods of using the polypeptide analogues described herein for treating cardiac dysfunction and other heart-related maladies. Yet another aspect of the present invention relates lo formulations comprising the polypeptide analogues described herein. | 10-06-2011 |
20110245174 | GLP-1 FUSION POLYPEPTIDES - We describe nucleic acid molecules that encode fusion polypeptides comprising GLP-1, or a receptor binding part thereof, linked directly or indirectly to a polypeptide that naturally binds GLP-1. | 10-06-2011 |
20110263502 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES - The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release. | 10-27-2011 |
20110275568 | METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE - The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases. | 11-10-2011 |
20110294735 | MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF - The use of neuromedin U receptor agonists to elevate the levels of GLP-1 and/or PYY in an individual in need of an increase in its levels of GLP-1 and/or PYY is described. Further described is the use of neuromedin U receptor agonists to lower the levels of glucagon in an individual in need of lowered glucagon levels. Thus, methods for elevating GLP-1 and/or PYY and lowering glucagon levels in an individual by administering to the individual compositions comprising a neuromedin U receptor agonist and optionally one or more dipeptidyl peptidase IV (DPP-IV) inhibitors are described. In light of the ability of NMU receptor agonists to raise GLP-1 and PYY levels and lower glucagon levels post-administration, methods are described for evaluating the efficacy of a treatment regimen for a metabolic disorder that includes administering a composition comprising a neuromedin U receptor agonist to an individual comprising measuring the level of glucagon-like peptide 1 (GLP-1) and/or peptide YY (PYY) and/or glucagon in the individual before, during, and after the treatment regimen. | 12-01-2011 |
20110306549 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS - The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. | 12-15-2011 |
20120077746 | GLP-1 ANALOGUES PHARMACEUTICAL COMPOSITIONS - The present invention is directed to sustained release liquid pharmaceutical compositions comprising a liquid, a peptide analogue according to the formula [Aib | 03-29-2012 |
20120101038 | USE OF GLP-1, GLP-1 DERIVATIVES OR GLP-1 FRAGMENTS FOR SKIN REGENERATION, STIMULATION OF HAIR GROWTH, OR TREATMENT OF DIABETES - The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes. | 04-26-2012 |
20120122783 | GLUCAGON ANTAGONISTS - Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid substitution at position 9 (according to the numbering of native glucagon) or (ii) substitution of the Phe at position 6 (according to the numbering of native glucagon) with phenyl lactic acid (PLA). In another embodiment, the glucagon antagonists comprise the structure A-B-C as described herein, wherein A is PLA, an oxy derivative thereof, or a peptide of 2-6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond. | 05-17-2012 |
20120157382 | PHARMACEUTICAL GLP-1 COMPOSITIONS HAVING AN IMPROVED RELEASE PROFILE - This invention relates to sustained release liquid pharmaceutical compositions containing a peptide analogue of glucagon-like peptide-1 or salts thereof having an improved release profile. The invention also relates to methods for preparing such compositions. | 06-21-2012 |
20120178687 | Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described. | 07-12-2012 |
20120196804 | GLUCAGON ANALOGS EXHIBITING PHYSIOLOGICAL SOLUBILITY AND STABILITY - Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both. | 08-02-2012 |
20120208755 | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers - The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered. | 08-16-2012 |
20120238497 | GLP-1 FUSION PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. | 09-20-2012 |
20120252727 | MUCOSAL DELIVERY OF THERAPEUTIC MOLECULES, PROTEINS, OR PARTICLES COUPLED TO CERAMIDE LIPIDS - Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER). | 10-04-2012 |
20120252728 | Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome - A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010. | 10-04-2012 |
20120270786 | INTESTINE AND MUSCLE RECOVERY - The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the secretion of GLP-2 in a body to treat or prevent muscle atrophy. | 10-25-2012 |
20120277154 | HOMODIMER OF INSULINOTROPIC PEPTIDE ANALOGUES AND METHOD FOR PREPARATION THEREOF AND USE THEREOF - Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs. | 11-01-2012 |
20120289466 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues. | 11-15-2012 |
20120295849 | USE OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders. | 11-22-2012 |
20120295850 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS - The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. | 11-22-2012 |
20120302501 | TREATMENT OF DIABETIC CARDIOMYOPATHY WITH A GLP-1 PEPTIDE - Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy. | 11-29-2012 |
20120302502 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION - Compositions and methods are provided for mucosal delivery of peptides. The compositions include a stably hydrated peptide active agent complexed with a crown compound and/or a counter ion solubilized in a non-aqueous hydrophobic vehicle at a pH different from the pI of the peptide active agent. The methods include administering to a subject an effective amount of a composition of the disclosure. Other aspects include methods for the manufacture of the compositions of the disclosure. Also provided are compositions and kits that find use in practicing embodiments of the disclosure. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions. | 11-29-2012 |
20120329715 | GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF - The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects. | 12-27-2012 |
20130012439 | COMPOSITION FOR NASAL ADMINISTRATION AND METHOD FOR PREPARING SAME - The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides. | 01-10-2013 |
20130040884 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG - Novel polypeptide derivatives having protracted profile of action. | 02-14-2013 |
20130053315 | NOVEL GLP-1 DERIVATIVES - Novel polypeptide derivatives having protracted profile of action. | 02-28-2013 |
20130053316 | Methods for Treating Disorders of the Gastrointestinal Tract Using a GLP-1 Agonist - The invention provides a method of treating a subject having, or at risk of developing, a condition in which functioning of the small or large intestine is impaired, enhancing functioning or preventing damage to the small or large intestine in a subject, or ameliorating inflammation of the small or large intestine in a subject, comprising administering to the subject a GLP-1 receptor agonist. A GLP-1 receptor agonist may also be provided in a pharmaceutically acceptable form in an amount effective to treat or prevent conditions of the small or large intestine. Further, pharmaceutical compositions are provided for the treatment or prevention of conditions of the small or large intestine comprising a GLP-1 receptor agonist, together with a pharmaceutically acceptable carrier, excipient or vehicle. | 02-28-2013 |
20130053317 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION - The present invention provides methods for treating, preventing and/or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and/or at least one GLP-1 agonist. | 02-28-2013 |
20130059780 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] - The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response. | 03-07-2013 |
20130072430 | METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION - Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs. | 03-21-2013 |
20130096059 | GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE BILIARY TRACT - The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated (a) stenosis or/and obstruction located in the biliary tract, or/and (b) biliary dyskinesia, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance. | 04-18-2013 |
20130096060 | GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE PANCREATIC DUCT SYSTEM - The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance. | 04-18-2013 |
20130116179 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE - The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease. | 05-09-2013 |
20130150296 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 06-13-2013 |
20130157953 | TREATMENT OF CARDIAC CONDITIONS - The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon. | 06-20-2013 |
20130157954 | METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION - Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs. | 06-20-2013 |
20130165379 | Formulations of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin, agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 06-27-2013 |
20130172257 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-04-2013 |
20130178420 | NOVEL GLP-1 RECEPTOR MODULATORS - The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 07-11-2013 |
20130203672 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use - The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels. | 08-08-2013 |
20130203673 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 08-08-2013 |
20130252893 | Novel Composition - There is provided according to the invention an aqueous composition having pH between 4 and 7 comprising (i) glucagon at a concentration of 0.05% w/v or more and (ii) a cationic surfactant selected from benzalkonium salts and benzethonium salts as solubilising agent in an amount sufficient to dissolve the glucagon in the composition. | 09-26-2013 |
20130252894 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER POLYPEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 09-26-2013 |
20130281373 | COMBINATION THERAPY - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. | 10-24-2013 |
20130281374 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 10-24-2013 |
20130338071 | GLP-1 Agonist and Cardiovascular Complications - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 12-19-2013 |
20130345134 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID - The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine. | 12-26-2013 |
20140031290 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS - Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided. | 01-30-2014 |
20140045754 | GLP-1 COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised in that the GLP-1:divalent metal molar ratio is 1:>2. The compositions of the invention are particularly useful in the treatment of diabetes. | 02-13-2014 |
20140080757 | GLUCAGON ANALOGUES - The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 03-20-2014 |
20140171370 | FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE - The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs. | 06-19-2014 |
20140187489 | MUCOSAL DELIVERY OF DRUGS - The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C | 07-03-2014 |
20140187490 | Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome - A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010. | 07-03-2014 |
20140200183 | TREATMENT OF CARDIAC ARRHYTHMIAS - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 07-17-2014 |
20140206615 | GLP-1 AGONIST AND CARDIOVASCULAR COMPLICATIONS - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 07-24-2014 |
20140206616 | Sustained-Release Lipid Pre-Concentrate of Pharmacologically Active Substance And Pharmaceutical Composition Comprising The Same - Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided. | 07-24-2014 |
20140213518 | METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE - The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases. | 07-31-2014 |
20140287998 | GLUCAGON FORMULATIONS - Glucagon is formulated in hydrochloric acid buffered, mannitol containing formulations that can be readily lyophilized and rapidly reconstituted for use in dual chamber cartridges and auto-injector device technology. | 09-25-2014 |
20140303083 | GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC—(CH2)x-CO—*, and Chem. 16: HOOC—C6H4-O—(CH2)y-CO—*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *—NH—CH(CH2OH)—CO—*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases. | 10-09-2014 |
20140309168 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 10-16-2014 |
20140309169 | Methods and Compositions for Inhibiting Delayed Graft Function - Disclosed are compositions and methods for inhibiting preventing, reducing delayed graft function, allograft rejection or ischemia reperfusion injury. | 10-16-2014 |
20140336118 | POLYPEPTIDE FOR THE PROTECTION AGAINST HEART ISCHEMIA-REPERFUSION INJURY - A peptide of the formula R | 11-13-2014 |
20140371148 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 12-18-2014 |
20140378381 | STABILIZED GLUCAGON NANOEMULSIONS - The present invention provides an oil-in-water nanoemulsion containing glucagon, an oily phase, and an aqueous phase, wherein the glucagon is physically and chemically stable and the nanoemulsion is suitable for administration by manual injection or by a pump to treat hypoglycemia. | 12-25-2014 |
20150038416 | NOVEL GLP-1 RECEPTOR MODULATORS - The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 02-05-2015 |
20150038417 | GLP-1 Agonists - A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist. | 02-05-2015 |
20150057227 | COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS - The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered. | 02-26-2015 |
20150080307 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 03-19-2015 |
20150080308 | Formulations and Uses of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 03-19-2015 |
20150111826 | ACYLATED GLUCAGON ANALOGUES - The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 04-23-2015 |
20150133384 | C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP-1) - C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome. | 05-14-2015 |
20150290294 | METHODS FOR INHIBITING PLATELET AGGREGATION USING GLP-1 RECEPTOR AGONISTS - Methods for inhibiting platelet aggregation using glucagon-like peptide-1 receptor (GLP-1R) agonists are disclosed. GLP-1 receptors are demonstrated to be expressed in platelets and/or megakaryocytes. Activation of GLP-1 receptors by GLP-1 agonists, such as GLP-1 and exendin-4, inhibited thrombin-induced platelet aggregation. | 10-15-2015 |
20150290296 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 10-15-2015 |
20150291680 | FORMULATIONS COMPRISING GLUCAGON - Glucagon formulations that resist fibril formation are disclosed. The formulations comprise curcumin derivatives such as ferulic acid and/or tetrahydrocurcumin and can further comprise human serum albumin, polysorbate-80, and L-methionine. | 10-15-2015 |
20150297573 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL - The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting β-cell survival and function in a number of applications. | 10-22-2015 |
20150344540 | NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY - The present invention provides novel glucagon-like protein-1 (GLP-1) receptor agonist compounds that promote cholesterol efflux. The ABCA1-mediated cholesterol efflux present invention also provides compositions comprising the novel glucagon-like protein-1(GLP-1) receptor agonist compounds, and relates to the use of said compounds in therapy, to methods of treatment comprising administration of said compounds to patients, and to the use of said compounds in the manufacture of medicaments. | 12-03-2015 |
20150374825 | Stable Glucagon Formulations - Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit ttle or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non- aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration. | 12-31-2015 |
20160000882 | PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE - The invention relates to peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa | 01-07-2016 |
20160002294 | NOVEL POLYPEPTIDES HAVING SATIETY HORMONE RELEASING ACTIVITY - The present invention relates to novel polypeptides having satiety hormone releasing activity (e.g., cholecystokinin (CCK) and/or glucagon-like peptide-1 (GLP-1) releasing activity). | 01-07-2016 |
20160015788 | TREATMENT OF NEUROLOGICAL DISEASES - Methods treat neurological disorders, for example neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke. Particularly although not exclusively, GIP/GLP-1 co-agonist peptide is used in the treatment of such neurological disorders. Pharmaceutical compositions include a GIP/GLP-1 co-agonist peptide for use in treatment of such disorders. | 01-21-2016 |
20160038500 | COMBINATION THERAPY - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. | 02-11-2016 |
20160067311 | USE OF ELSIGLUTIDE TO TREAT GASTROINTESTINAL MUCOSITIS INCLUDING CHEMOTHERAPY-INDUCED DIARRHEA - The invention relates to the use of elsiglutide to prevent or reduce the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). | 03-10-2016 |
20160137711 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2-related conditions. | 05-19-2016 |
20160151461 | Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites | 06-02-2016 |
20160151462 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 06-02-2016 |
20170232073 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | 08-17-2017 |
20180021346 | NOVEL GLP-1 RECEPTOR MODULATORS | 01-25-2018 |
20180021409 | Pharmaceutical Composition | 01-25-2018 |
20190142905 | PEPTIDE-OLIGOUREA FOLDAMER COMPOUNDS AND METHODS OF THEIR USE | 05-16-2019 |